This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBiotechnology Assets (041) 주식 개요바이오테크놀로지 에셋은 스페인 및 전 세계의 바이오 제약, 농화학, 화장품, 수의학, 화학 산업 분야에 적용할 수 있는 바이오테크놀로지 자산을 개발 및 판매하는 회사입니다. 자세히 보기041 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적0/6재무 건전성3/6배당0/6강점지난 5년 동안 수입이 매년 5.9% 증가했습니다.위험 분석의미 있는 시가총액이 없습니다(€20M)의미 있는 수익이 없습니다(€3M)지난 3개월 동안 주가 변동성이 German 시장과 비교해 높았습니다.모든 위험 점검 보기041 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.2527.7% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-17m38m2016201920222025202620282031Revenue €12.3mEarnings €2.2mAdvancedSet Fair ValueView all narrativesBiotechnology Assets, S.A. 경쟁사Genetic AnalysisSymbol: DB:8V8Market cap: €42.7mDarwinSymbol: MUN:7V0Market cap: €68.4mFormyconSymbol: XTRA:FYBMarket cap: €354.3mDextech MedicalSymbol: DB:LQ0Market cap: €184.9m가격 이력 및 성과Biotechnology Assets 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가€0.2552주 최고가€0.5252주 최저가€0.11베타1.781개월 변동13.45%3개월 변동19.91%1년 변동14.48%3년 변동-1.56%5년 변동-56.68%IPO 이후 변동-87.60%최근 뉴스 및 업데이트공시 • May 19Biotechnology Assets, S.A., Annual General Meeting, Jun 18, 2025Biotechnology Assets, S.A., Annual General Meeting, Jun 18, 2025. Location: hotel melia madrid serrano, calle claudio coello 139., madrid SpainReported Earnings • May 19Full year 2024 earnings releasedFull year 2024 results: Revenue: €2.97m (down 24% from FY 2023). Net loss: €2.92m (down 285% from profit in FY 2023).New Risk • May 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (€3.4m revenue, or US$3.8m). Market cap is less than US$100m (€20.2m market cap, or US$22.6m).New Risk • Apr 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (€3.4m revenue, or US$3.8m). Market cap is less than US$100m (€21.2m market cap, or US$24.1m).New Risk • Oct 23New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.2% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (€3.9m revenue, or US$4.2m). Market cap is less than US$100m (€19.5m market cap, or US$21.1m).공시 • May 21Biotechnology Assets, S.A., Annual General Meeting, Jun 19, 2024Biotechnology Assets, S.A., Annual General Meeting, Jun 19, 2024. Location: hotel melia madrid serrano, calle claudio coello 139., madrid Spain더 많은 업데이트 보기Recent updates공시 • May 19Biotechnology Assets, S.A., Annual General Meeting, Jun 18, 2025Biotechnology Assets, S.A., Annual General Meeting, Jun 18, 2025. Location: hotel melia madrid serrano, calle claudio coello 139., madrid SpainReported Earnings • May 19Full year 2024 earnings releasedFull year 2024 results: Revenue: €2.97m (down 24% from FY 2023). Net loss: €2.92m (down 285% from profit in FY 2023).New Risk • May 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (€3.4m revenue, or US$3.8m). Market cap is less than US$100m (€20.2m market cap, or US$22.6m).New Risk • Apr 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (€3.4m revenue, or US$3.8m). Market cap is less than US$100m (€21.2m market cap, or US$24.1m).New Risk • Oct 23New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.2% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (€3.9m revenue, or US$4.2m). Market cap is less than US$100m (€19.5m market cap, or US$21.1m).공시 • May 21Biotechnology Assets, S.A., Annual General Meeting, Jun 19, 2024Biotechnology Assets, S.A., Annual General Meeting, Jun 19, 2024. Location: hotel melia madrid serrano, calle claudio coello 139., madrid SpainNew Risk • Apr 11New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 9.9% over the past year. Minor Risks Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.2m). Market cap is less than US$100m (€21.3m market cap, or US$22.9m).New Risk • Dec 31New major risk - Revenue and earnings growthRevenue has declined by 9.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue has declined by 9.9% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (6.8% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.3m). Market cap is less than US$100m (€22.8m market cap, or US$25.2m).New Risk • Oct 29New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (14% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.1m). Market cap is less than US$100m (€23.7m market cap, or US$25.0m).Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Javier Luz was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Javier Luz was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 03First half 2021 earnings releasedThe company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: (down 100% from 1H 2020). Net income: (up €10.0m from 1H 2020). Profit margin: (up from net loss in 1H 2020). The move to profitability was driven by lower expenses.Is New 90 Day High Low • Feb 16New 90-day high: €1.20The company is up 206% from its price of €0.39 on 18 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period.Is New 90 Day High Low • Jan 09New 90-day high: €0.97The company is up 425% from its price of €0.18 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is flat over the same period.Is New 90 Day High Low • Dec 08New 90-day high: €0.50The company is up 4.0% from its price of €0.48 on 09 September 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 11% over the same period.공시 • Oct 08Kartesia Advisor LLP acquired 51% stake in ADL Biopharma from ADL Bionatur Solutions, S.A. (BME:ADL) and Black Toro Capital LLP.Kartesia Advisor LLP acquired 51% stake in ADL Biopharma from ADL Bionatur Solutions, S.A. (BME:ADL) and Black Toro Capital LLP on October 7, 2020. The agreement also includes a new tranche of €5 million made available at closing by Kartesia for the general corporate purposes of ADL, a commitment by the shareholders to approve a capital increase of at least €10 million to be completed before year-end, pro rata of the stake of each party, and the A&E (an amend and extend facility) of the senior financing. With immediate effect, ADL Biopharma will operate as an independent entity from ADL Bionatur Solutions. The Board of Directors has been expanded to 5 seats with the appointment of 3 new independent Directors: Raúl Crespo (Deloitte, Oquendo, KPMG), Ignacio Urbelz (Calidad Pascual, Vivesoy, HP) and Mirco Iwan (Capua Bioservices, Eismann), adding relevant expertise in key areas such as finance, operations and sales. Kartesia Advisor LLP completed the acquisition of 51% stake in ADL Biopharma from ADL Bionatur Solutions, S.A. (BME:ADL) and Black Toro Capital LLP on October 7, 2020.공시 • Jul 17ADL Bionatur Solutions, S.A. Auditor Raises 'Going Concern' DoubtADL Bionatur Solutions, S.A. filed its Annual on Jun 22, 2020 for the period ending Dec 31, 2019. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.주주 수익률041DE BiotechsDE 시장7D2.4%1.8%2.4%1Y14.5%-12.5%1.2%전체 주주 수익률 보기수익률 대 산업: 041은 지난 1년 동안 -12.5%의 수익을 기록한 German Biotechs 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: 041은 지난 1년 동안 1.2%를 기록한 German 시장보다 더 좋은 성과를 냈습니다.주가 변동성Is 041's price volatile compared to industry and market?041 volatility041 Average Weekly Movement10.8%Biotechs Industry Average Movement8.5%Market Average Movement6.1%10% most volatile stocks in DE Market13.4%10% least volatile stocks in DE Market2.7%안정적인 주가: 041의 주가는 지난 3개월 동안 German 시장보다 변동성이 컸습니다.시간에 따른 변동성: 041의 주간 변동성은 지난 1년간 38%에서 11%로 감소했지만 여전히 German 종목의 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트n/a30n/awww.biatgroup.com바이오테크놀로지 에셋은 스페인 및 전 세계의 바이오 제약, 농화학, 화장품, 수의학, 화학 산업 분야에 적용할 수 있는 바이오테크놀로지 자산을 개발 및 판매하는 회사입니다. 이 회사는 1954년에 설립되었으며 스페인 카디스에 본사를 두고 있습니다.더 보기Biotechnology Assets, S.A. 기초 지표 요약Biotechnology Assets의 순이익과 매출은 시가총액과 어떻게 비교됩니까?041 기초 통계시가총액€20.13m순이익 (TTM)-€2.08m매출 (TTM)€3.05m6.6x주가매출비율(P/S)-9.7x주가수익비율(P/E)041는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표041 손익계산서 (TTM)매출€3.05m매출원가€291.56k총이익€2.76m기타 비용€4.84m순이익-€2.08m최근 보고된 실적Jun 30, 2025다음 실적 발표일해당 없음주당순이익(EPS)-0.028총이익률90.45%순이익률-68.10%부채/자본 비율33.2%041의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/01 19:42종가2026/04/29 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Biotechnology Assets, S.A.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Pooya HemamiEdison Investment ResearchIñigo Recio PascualGVC Gaesco Valores
공시 • May 19Biotechnology Assets, S.A., Annual General Meeting, Jun 18, 2025Biotechnology Assets, S.A., Annual General Meeting, Jun 18, 2025. Location: hotel melia madrid serrano, calle claudio coello 139., madrid Spain
Reported Earnings • May 19Full year 2024 earnings releasedFull year 2024 results: Revenue: €2.97m (down 24% from FY 2023). Net loss: €2.92m (down 285% from profit in FY 2023).
New Risk • May 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (€3.4m revenue, or US$3.8m). Market cap is less than US$100m (€20.2m market cap, or US$22.6m).
New Risk • Apr 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (€3.4m revenue, or US$3.8m). Market cap is less than US$100m (€21.2m market cap, or US$24.1m).
New Risk • Oct 23New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.2% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (€3.9m revenue, or US$4.2m). Market cap is less than US$100m (€19.5m market cap, or US$21.1m).
공시 • May 21Biotechnology Assets, S.A., Annual General Meeting, Jun 19, 2024Biotechnology Assets, S.A., Annual General Meeting, Jun 19, 2024. Location: hotel melia madrid serrano, calle claudio coello 139., madrid Spain
공시 • May 19Biotechnology Assets, S.A., Annual General Meeting, Jun 18, 2025Biotechnology Assets, S.A., Annual General Meeting, Jun 18, 2025. Location: hotel melia madrid serrano, calle claudio coello 139., madrid Spain
Reported Earnings • May 19Full year 2024 earnings releasedFull year 2024 results: Revenue: €2.97m (down 24% from FY 2023). Net loss: €2.92m (down 285% from profit in FY 2023).
New Risk • May 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (€3.4m revenue, or US$3.8m). Market cap is less than US$100m (€20.2m market cap, or US$22.6m).
New Risk • Apr 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (€3.4m revenue, or US$3.8m). Market cap is less than US$100m (€21.2m market cap, or US$24.1m).
New Risk • Oct 23New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.2% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (€3.9m revenue, or US$4.2m). Market cap is less than US$100m (€19.5m market cap, or US$21.1m).
공시 • May 21Biotechnology Assets, S.A., Annual General Meeting, Jun 19, 2024Biotechnology Assets, S.A., Annual General Meeting, Jun 19, 2024. Location: hotel melia madrid serrano, calle claudio coello 139., madrid Spain
New Risk • Apr 11New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 9.9% over the past year. Minor Risks Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.2m). Market cap is less than US$100m (€21.3m market cap, or US$22.9m).
New Risk • Dec 31New major risk - Revenue and earnings growthRevenue has declined by 9.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue has declined by 9.9% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (6.8% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.3m). Market cap is less than US$100m (€22.8m market cap, or US$25.2m).
New Risk • Oct 29New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (14% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.1m). Market cap is less than US$100m (€23.7m market cap, or US$25.0m).
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Javier Luz was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Javier Luz was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 03First half 2021 earnings releasedThe company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: (down 100% from 1H 2020). Net income: (up €10.0m from 1H 2020). Profit margin: (up from net loss in 1H 2020). The move to profitability was driven by lower expenses.
Is New 90 Day High Low • Feb 16New 90-day high: €1.20The company is up 206% from its price of €0.39 on 18 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period.
Is New 90 Day High Low • Jan 09New 90-day high: €0.97The company is up 425% from its price of €0.18 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is flat over the same period.
Is New 90 Day High Low • Dec 08New 90-day high: €0.50The company is up 4.0% from its price of €0.48 on 09 September 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 11% over the same period.
공시 • Oct 08Kartesia Advisor LLP acquired 51% stake in ADL Biopharma from ADL Bionatur Solutions, S.A. (BME:ADL) and Black Toro Capital LLP.Kartesia Advisor LLP acquired 51% stake in ADL Biopharma from ADL Bionatur Solutions, S.A. (BME:ADL) and Black Toro Capital LLP on October 7, 2020. The agreement also includes a new tranche of €5 million made available at closing by Kartesia for the general corporate purposes of ADL, a commitment by the shareholders to approve a capital increase of at least €10 million to be completed before year-end, pro rata of the stake of each party, and the A&E (an amend and extend facility) of the senior financing. With immediate effect, ADL Biopharma will operate as an independent entity from ADL Bionatur Solutions. The Board of Directors has been expanded to 5 seats with the appointment of 3 new independent Directors: Raúl Crespo (Deloitte, Oquendo, KPMG), Ignacio Urbelz (Calidad Pascual, Vivesoy, HP) and Mirco Iwan (Capua Bioservices, Eismann), adding relevant expertise in key areas such as finance, operations and sales. Kartesia Advisor LLP completed the acquisition of 51% stake in ADL Biopharma from ADL Bionatur Solutions, S.A. (BME:ADL) and Black Toro Capital LLP on October 7, 2020.
공시 • Jul 17ADL Bionatur Solutions, S.A. Auditor Raises 'Going Concern' DoubtADL Bionatur Solutions, S.A. filed its Annual on Jun 22, 2020 for the period ending Dec 31, 2019. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
